人工智能在心脏衰竭管理中的作用
Baljash Cheema1, Jonathan Hourmozdi2, Adrienne Kline1
1Bluhm Cardiovascular Institute, Center for Artificial Intelligence, Northwestern Medicine, Chicago, IL; Northwestern University, Feinberg School of Medicine, Chicago, IL.
Journal of cardiac failure
|May 9, 2025
概括
人工智能 (AI) 在心力衰竭管理中提供了变革性的潜力,从诊断到个性化治疗. 克服数据隐私和信任等实施障碍对于这些先进的AI工具的广泛临床采用至关重要.
科学领域:
- 心脏病学 心脏病学
- 医疗信息学 医疗信息学
- 人工智能的人工智能
背景情况:
- 心力衰竭管理在诊断和治疗方面存在复杂的挑战.
- 人工智能 (AI) 已经成为一种强大的工具,有可能显著改善患者护理.
- 在过去的十年中,许多人工智能解决方案已经开发出来,以解决心力衰竭的各个方面.
研究的目的:
- 审查人工智能在心力衰竭的诊断和管理中的进展和应用.
- 通过多式联网数据集成,突出AI在个性化患者护理方面的潜力.
- 确定和讨论阻碍AI在心力衰竭中临床实施的关键障碍.
主要方法:
- 整合多式联运数据,包括电磁信息,成像,信号和电子健康记录.
- 应用最先进的算法来定制患者护理.
- 审查现有的AI解决方案及其对心力衰竭管理的影响.
主要成果:
- 人工智能工具可以帮助诊断风险因素,识别结构性心脏病,改善心肌病诊断和管理症状性心力衰竭.
- 人工智能通过整合多种数据源,使患者护理能够更加个性化.
- 在开发心力衰竭人工智能解决方案方面取得了重大进展.
结论:
- 人工智能为彻底改变心力衰竭护理提供了巨大的希望.
- 必须解决关键的实施挑战,包括数据隐私,模型性能,集成,信任,治理,公平和偏见.
- 进一步的研究和最佳实践的开发对于加速AI在心力衰竭管理中的临床采用至关重要.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
316
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
316
Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
Heart Failure Drugs: Inotropic Agents
416
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
416
Heart Failure Drugs: β-Blockers
273
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
273
Heart Failure Drugs: Diuretics
291
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
291


